Your browser doesn't support javascript.
loading
Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases.
Ordutowski, Henry; Dal Dosso, Francesco; De Wispelaere, Wout; Van Tricht, Charlotte; Vermeire, Séverine; Geukens, Nick; Gils, Ann; Spasic, Dragana; Lammertyn, Jeroen.
Afiliação
  • Ordutowski H; Department of Biosystems, Biosensors Group, KU Leuven, Belgium.
  • Dal Dosso F; Department of Biosystems, Biosensors Group, KU Leuven, Belgium.
  • De Wispelaere W; Department of Biosystems, Biosensors Group, KU Leuven, Belgium.
  • Van Tricht C; Department of Biosystems, Biosensors Group, KU Leuven, Belgium.
  • Vermeire S; Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Belgium.
  • Geukens N; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium; PharmAbs, The KU Leuven Antibody Center, Leuven, Belgium.
  • Gils A; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
  • Spasic D; Department of Biosystems, Biosensors Group, KU Leuven, Belgium. Electronic address: dragana.spasic@kuleuven.be.
  • Lammertyn J; Department of Biosystems, Biosensors Group, KU Leuven, Belgium. Electronic address: jeroen.lammertyn@kuleuven.be.
Biosens Bioelectron ; 208: 114189, 2022 Jul 15.
Article em En | MEDLINE | ID: mdl-35366427
ABSTRACT
Therapeutic drug monitoring (TDM) of adalimumab (ADM) at the point-of-care (POC) is key to prevent loss of response but has not been accomplished to date because true POC testing solutions are still lacking. Here, we present a novel "whole blood in - result out" self-powered microfluidic chip for detecting ADM within 30 min to enable TDM at POC. Hereto, we first demonstrated on-chip plasma separation from whole blood, followed by downscaling an ADM ELISA with maintained specificity and sensitivity in plasma. This assay was then performed on a robust and easy-to-use microfluidic chip we designed based on (i)SIMPLE technology, allowing autonomous function upon single finger press activation, which was successfully validated with patient samples. Herein, we prove the potential of our technology to detect targets starting from whole blood introduced directly on-chip and to integrate various immunoassays, both for TDM and other in vitro diagnostics applications, like infectious diseases.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Técnicas Biossensoriais Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Técnicas Biossensoriais Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article